UroGen Pharma Ltd. Reports Board and Executive Changes

TL;DR

UroGen Pharma reshuffled its board and exec comp effective 6/30.

AI Summary

UroGen Pharma Ltd. announced on June 30, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. These changes are effective as of June 30, 2025.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.

Risk Assessment

Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect future performance or strategy.

Key Players & Entities

• UroGen Pharma Ltd. (company) — Registrant
• June 30, 2025 (date) — Effective date of reported changes

FAQ

From the Filing

0001193125-25-155503.txt : 20250703 0001193125-25-155503.hdr.sgml : 20250703 20250703161610 ACCESSION NUMBER: 0001193125-25-155503 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250630 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 251105760 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 d941822d8k.htm 8-K 8-K false 0001668243 0001668243 2025-06-30 2025-06-30     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025     UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter)       Israel   001-38079   98-1460746 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   400 Alexander Park Drive , 4th Floor Princeton , New Jersey   08540 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: +1 (646) 768-9780     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary Shares, par value NIS 0.01 per share   URGN   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On June 30, 2025, the Board of Directors of UroGen Pharma Ltd. (the “Company”) approved one-time special bonuses of $645,000, $100,000 and $100,000 to Elizabeth Barrett, the Company’s President and Chief Executive Officer, Chris Degnan, the Company’s Chief Financial Officer, and Jason Smith, the Company’s General Counsel and Chief Compliance Officer, respectively. The special bonuses were awarded in recognition of each named executive officer’s leadership and contributions le